AMICUS THERAPEUTICS INC (FOLD) Stock Analyst Ratings
USA - NASDAQ:FOLD - US03152W1099 - Common Stock
9.42 USD
+0.1 (+1.07%)
9.42 USD
0 (0%)
ChartMill assigns a Buy % Consensus number of 85% to FOLD. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 16.32. This target is 73.25% above the current price.
FOLD was analyzed by 17 analysts. The buy percentage consensus is at 85. So analysts seem to be very confident about FOLD.
In the previous month the buy percentage consensus was at a similar level.
FOLD was analyzed by 17 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-11-06 | JP Morgan | Maintains | Overweight -> Overweight |
| 2025-11-05 | Goldman Sachs | Maintains | Neutral -> Neutral |
| 2025-09-18 | Needham | Upgrade | Hold -> Buy |
| 2025-07-17 | Morgan Stanley | Upgrade | Equal-Weight -> Overweight |
| 2025-05-02 | UBS | Maintains | Buy -> Buy |
| 2025-05-02 | Goldman Sachs | Maintains | Neutral -> Neutral |
| 2025-02-20 | Needham | Reiterate | Hold -> Hold |
| 2025-02-20 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2025-01-15 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2025-01-13 | Needham | Reiterate | Hold -> Hold |
| 2024-12-13 | Morgan Stanley | Downgrade | Overweight -> Equal-Weight |
| 2024-11-12 | JP Morgan | Maintains | Overweight -> Overweight |
| 2024-11-07 | Cantor Fitzgerald | Maintains | Overweight -> Overweight |
| 2024-11-07 | Guggenheim | Maintains | Buy -> Buy |
| 2024-11-07 | Needham | Reiterate | Hold |
| 2024-10-17 | B of A Securities | Maintains | Buy -> Buy |
| 2024-10-11 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2024-09-20 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2024-09-06 | Jefferies | Initiate | Buy |
| 2024-08-16 | JP Morgan | Maintains | Overweight -> Overweight |
| 2024-08-09 | Needham | Reiterate | Hold |
| 2024-05-30 | Wells Fargo | Initiate | Overweight |
| 2024-05-14 | Guggenheim | Upgrade | Neutral -> Buy |
| 2024-05-10 | UBS | Maintains | Buy -> Buy |
| 2024-05-10 | Needham | Reiterate | Hold |
| 2024-05-10 | B of A Securities | Maintains | Buy -> Buy |
| 2024-05-10 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2024-03-18 | JP Morgan | Maintains | Overweight -> Overweight |
| 2024-02-29 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2023-12-19 | Morgan Stanley | Upgrade | Equal-Weight -> Overweight |
AMICUS THERAPEUTICS INC / FOLD FAQ
Can you provide the average price target for AMICUS THERAPEUTICS INC stock?
17 analysts have analysed FOLD and the average price target is 16.32 USD. This implies a price increase of 73.25% is expected in the next year compared to the current price of 9.42.
What is the consensus rating for AMICUS THERAPEUTICS INC (FOLD) stock?
The consensus rating for AMICUS THERAPEUTICS INC (FOLD) is 84.7059 / 100 . This indicates that analysts generally have a positive outlook on the stock.
How many analysts cover AMICUS THERAPEUTICS INC (FOLD) stock?
The number of analysts covering AMICUS THERAPEUTICS INC (FOLD) is 17.